BioAscend

🚨 Don’t Miss This at #AATS2026 🚨 Join us for a 1-hour program examining how pathologic complete response (pCR) is defined, assessed, and operationalized in clinical trials for resectable #NSCLC. 📆 May 4, 2026 at 12:00 PM CT Sign Up Now: loom.ly/EwBh-jg

Expert faculty are diving into the clinical and operational sides of pCR—its definition, assessment, and role in trials and how it shapes adjuvant treatment decisions alongside other prognostic biomarkers. Sign up now to stay ahead in the field. 🔗 loom.ly/EwBh-jg #AATS2026 #NSCLC

✨Last Chance to Join Harvesting Knowledge: A Summit on #MultipleMyeloma 📍 Napa, CA 🗓️ April 25, 2026 🔗‍️ loom.ly/Ziv2EZ8 Register today for #MMSummit26—a focused, clinically-driven summit designed to equip health care professionals with the latest evidence‑based insights and practical strategies for managing multiple myeloma across the full continuum of care. #Oncology #MM #CME

Why attend #MMSummit2026 in Napa on April 25? Because the MM treatment landscape is evolving fast—this program is designed to address your most pressing clinical concerns Join expert faculty to: • Align treatment strategies across SMM, NDMM, and RRMM • Optimize sequencing—what to start, when to switch, and how to personalize • Apply real-world insights from recently-approved therapies, including bispecific antibodies • Strengthen AE mitigation strategies to sustain outcomes 📍 Napa, CA | April 25 🔗‍️Register Today: loom.ly/Ziv2EZ8 #MultipleMyeloma #Oncology #Hematology

How does pCR in clinical trials translate to real-world surgical practice? Join us Monday, May 2 | 12–1PM CT | #AATS2026 📋 Agenda highlights: 🔹The Evolving Role of pCR in Clinical Trials 🔹Protocols for Assessing pCR 🔹Prognostic Biomarkers: Escalate or De-Escalate? 🔹Panel: Multidisciplinary Roles of the Pathologist & Surgeon Register: loom.ly/EwBh-jg #NSCLC #AATS2026

SPONSORED: Join us for a 1-hour program examining how pathologic complete response (pCR) is defined, assessed, and operationalized in clinical trials for resectable #NSCLC. #AATS2026 May 4, 2026 at 12:00 PM CT Sign Up Now: loom.ly/EwBh-jg

Join us for a 1-hour program examining how pathologic complete response (pCR) is defined, assessed, and operationalized in clinical trials for resectable #NSCLC. 📆 May 4, 2026 at 12:00 PM CT 📍 #AATS2026 Sign Up Now: loom.ly/EwBh-jg

✨Harvesting Knowledge: A Summit on Multiple Myeloma✨ Dive deep into today’s most pressing myeloma challenges, through expert panels, live polling, and open Q&A. Napa, CA | April 25, 2026 🔗 Save your seat: loom.ly/Ziv2EZ8 #MM #Oncology #Hematology #MedEd #MMSummit2026

Thank you all for a successful and engaging #IUCLS2026 and be sure and save the date for #IUCLS2027 on April 9-10, 2027!

The Keynote Presentation at #IUCLS2026 is from Dr. Michael E Williams from @uvahealthnews discussing the evolution of treatment for mantle cell lymphoma. Are chemo-free regimens the wave of the future?

Should all patients with lymphoma need to undergo next generation sequencing/profiling?

The panel for the mini symposium on the most common lymphoma subtype #DLBCL discusses the current and emerging approaches to the frontline treatment of this disease including moving beyond R-CHOP #IUCLS2026 @JoshuaBrodyMD @tanaya_shree.

Co-chair @timfenske guides the final mini symposium of the day at #IUCLS2026 that focuses on follicular lymphoma. An important question asked by @NGhoshMD is: can follicular lymphoma be cured?

Co-chair Dr Neha Mehta-Shah from @washumedicine kicks off the general session at #IUCLS2026 by leading a mini symposium on #CLL. Esteemed faculty for this session include @mshadman @DrMDavids and Dr Elijah Darnell from @UChicagoMed.

Co-chair Dr Sonali Smith from @UChicagoMed leads our next interprofessional mini symposium focused on optimizing the long-term care of the lymphoma survivor at #IUCLS2026. How do you manage complications such as bone health, neuropathy, and cardiovascular issues?

We kick off the interprofessional session at #IUCLS2026 with co-chair @DrAEvens moderating a mini symposium on Hodgkin lymhoma. Topics include recent advances for both early-stage and advanced stage disease, as well as mananging complications of immune checkpoint inhibitors.

Efficacy is only part of the equation. At #MMSummit2026, faculty will share strategies to prevent, detect, and manage treatment-related toxicities, helping you mitigate adverse events while sustaining long-term outcomes. Support optimal and sustained #patientoutcomes through effective management. 📍 Napa, CA | April 25 🔗‍️ loom.ly/Ziv2EZ8 #MM #Oncology #AdverseEvents

⏳ Final Opportunity to Register for #IUCLS2026 Join us for the 23rd Chicago Lymphoma Symposium, a 2-day, thought-provoking event bringing together leading experts dedicated to advancing #lymphoma science and transforming clinical care. 📍 Location: Chicago 🗓 Dates: April 10-11, 2026 🔖 #IUCLS2026 Register today: loom.ly/X9eR-x8 #IUCLS2026 #Lymphoma #CME

Expert faculty are diving into the clinical and operational sides of pCR—its definition, assessment, and role in trials and how it shapes adjuvant treatment decisions alongside other prognostic biomarkers. Sign up now to stay ahead in the field. 🔗 loom.ly/EwBh-jg #AATS2026 #NSCLC

⭐ #IUCLS2026 Mini‑Symposium: #MZL ⭐ 🔹 Strategies for Frontline Therapy for MZL 🔹 MZL Biology and Rational Targets Secure your spot: loom.ly/X9eR-x8 #LYMSM #CancerCare #PrecisionOncology #CME